Penumbra (PEN) Stock Overview
Designs, develops, manufactures, and markets medical devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PEN from our risk checks.
PEN Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$254.94 |
| 52 Week High | US$310.00 |
| 52 Week Low | US$198.68 |
| Beta | 0.41 |
| 1 Month Change | -6.52% |
| 3 Month Change | 8.76% |
| 1 Year Change | 23.39% |
| 3 Year Change | 37.78% |
| 5 Year Change | 19.93% |
| Change since IPO | 517.29% |
Recent News & Updates
Recent updates
Results: Penumbra, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 01
Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner
Jun 26The Return Trends At Penumbra (NYSE:PEN) Look Promising
Jun 23Why Investors Shouldn't Be Surprised By Penumbra, Inc.'s (NYSE:PEN) P/S
May 26We Think You Can Look Beyond Penumbra's (NYSE:PEN) Lackluster Earnings
Apr 30Earnings Beat: Penumbra, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 26Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy
Mar 13Penumbra (NYSE:PEN) Will Be Hoping To Turn Its Returns On Capital Around
Jan 27Penumbra: Re-Rated For The Wrong Reasons
Jan 07Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects
Dec 31
CAVT Technology Powers Thrombectomy Leader To Transformative Growth And Global Expansion
Introduction of CAVT technology positions Penumbra as a thrombectomy leader, driving revenue growth through innovation and market share gains.Penumbra Grinding Through A Painful Growth Expectations Reset
Aug 20Penumbra: Appeal Improves As Operating Leverage Continues
May 30Penumbra: Appeal Improves, Just Not Appealing Yet
Oct 16Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01Shareholder Returns
| PEN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.4% | -0.9% | -1.1% |
| 1Y | 23.4% | -1.7% | 15.5% |
Return vs Industry: PEN exceeded the US Medical Equipment industry which returned -3.5% over the past year.
Return vs Market: PEN exceeded the US Market which returned 14.4% over the past year.
Price Volatility
| PEN volatility | |
|---|---|
| PEN Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 4,500 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
Penumbra, Inc. Fundamentals Summary
| PEN fundamental statistics | |
|---|---|
| Market cap | US$9.87b |
| Earnings (TTM) | US$147.70m |
| Revenue (TTM) | US$1.28b |
Is PEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEN income statement (TTM) | |
|---|---|
| Revenue | US$1.28b |
| Cost of Revenue | US$429.27m |
| Gross Profit | US$850.88m |
| Other Expenses | US$703.18m |
| Earnings | US$147.70m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 3.79 |
| Gross Margin | 66.47% |
| Net Profit Margin | 11.54% |
| Debt/Equity Ratio | 0% |
How did PEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/14 04:39 |
| End of Day Share Price | 2025/10/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Penumbra, Inc. is covered by 28 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| null null | Baird |
| Joanne Wuensch | BMO Capital Markets Equity Research |